The Notice of NMPA on the Management Category of Sodium Hyaluronate Products for Medical Purposes (2022 No. 103) was issued on Nov.14, 2022. It aims to strengthen the supervision and management of medical sodium hyaluronate products, further standardize the registration (filing) of related products, and ensure the safety and effectiveness of public medicinal devices, which includes relevant policies, regulations, and measures.
- Local Title:国家药监局关于医用透明质酸钠产品管理类别的公告（2022年第103号）
- Country/Region:Chinese Mainland
- Competent Authority: National Medical Products Administration (NMPA)
- Type:Notice
- Status:In force
- Release Date:2022-11-14
- Implementation Date:2022-11-14